40 related articles for article (PubMed ID: 22222334)
1. The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine.
Yang Y; Niu X; Zhang Q; Hao L; Ding Y; Xu H
Am J Med Sci; 2012 Sep; 344(3):199-205. PubMed ID: 22222334
[TBL] [Abstract][Full Text] [Related]
2. Total aglycones from Marsdenia tenacissima increases antitumor efficacy of paclitaxel in nude mice.
Zhu RJ; Shen XL; Dai LL; Ai XY; Tian RH; Tang R; Hu YJ
Molecules; 2014 Sep; 19(9):13965-75. PubMed ID: 25197933
[TBL] [Abstract][Full Text] [Related]
3. Sustained delivery of vincristine inside an orthotopic mouse sarcoma model decreases tumor growth.
Harris JC; Coburn JM; Kajdacsy-Balla A; Kaplan DL; Chiu B
J Pediatr Surg; 2016 Dec; 51(12):2058-2062. PubMed ID: 27680598
[TBL] [Abstract][Full Text] [Related]
4. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
[TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
[TBL] [Abstract][Full Text] [Related]
6. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
[TBL] [Abstract][Full Text] [Related]
7. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
Ernsting MJ; Murakami M; Undzys E; Aman A; Press B; Li SD
J Control Release; 2012 Sep; 162(3):575-81. PubMed ID: 22967490
[TBL] [Abstract][Full Text] [Related]
8. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE
PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921
[TBL] [Abstract][Full Text] [Related]
9. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA
Cancer Discov; 2012 Mar; 2(3):260-269. PubMed ID: 22585996
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
[TBL] [Abstract][Full Text] [Related]
11. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
Seong G; D'Angelo SP
Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of cancer nanotechnology in the panorama of sarcoma.
Mercatali L; Vanni S; Miserocchi G; Liverani C; Spadazzi C; Cocchi C; Calabrese C; Gurrieri L; Fausti V; Riva N; Genovese D; Lucarelli E; Focarete ML; Ibrahim T; Calabrò L; De Vita A
Front Bioeng Biotechnol; 2022; 10():953555. PubMed ID: 36324885
[TBL] [Abstract][Full Text] [Related]
13. Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells.
Kazantseva L; Becerra J; Santos-Ruiz L
Pharmacol Rep; 2022 Feb; 74(1):248-256. PubMed ID: 34427908
[TBL] [Abstract][Full Text] [Related]
14. Additive manufacturing of hydrogel-based materials for next-generation implantable medical devices.
Yin Chin S; Cheung Poh Y; Kohler AC; Compton JT; Hsu LL; Lau KM; Kim S; Lee BW; Lee FY; Sia SK
Sci Robot; 2017 Jan; 2(2):. PubMed ID: 31289767
[TBL] [Abstract][Full Text] [Related]
15. Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma.
Martella E; Ferroni C; Guerrini A; Ballestri M; Columbaro M; Santi S; Sotgiu G; Serra M; Donati DM; Lucarelli E; Varchi G; Duchi S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463350
[TBL] [Abstract][Full Text] [Related]
16. Expression and significance of secreted protein acidic and rich in cysteine in human osteosarcoma.
Yang Y; Niu X; Liu W; Xu H
Oncol Lett; 2017 Nov; 14(5):5491-5496. PubMed ID: 29142603
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
18. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
[TBL] [Abstract][Full Text] [Related]
19. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
